Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries
Open accessAbstract
Drug shortages have been identified as a public health problem in an increasing number of countries. This can negatively impact on the quality and efficiency of patient care, as well as contribute to increases in the cost of treatment and the workload of health care providers. Shortages also raise ethical and political issues. The scientific evidence on drug shortages is still scarce, but many lessons can be drawn from cross-country analyses. The objective of this study was to characterize, compare, and evaluate the current systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages within health care systems across a range of European and Western Asian countries. The study design was retrospective, cross-sectional, descriptive, and observational. Information was gathered through a survey distributed among senior personnel from ministries of health, state medicines agencies, local health authorities, other health or pharmaceutical pricing and reimbursement authorities, health insurance companies and academic institutions, with knowledge of the pharmaceutical markets in the 28 countries studied. Our study found that formal definitions of drug shortages currently exist in only a few countries. The characteristics of drug shortages, including their assortment, duration, frequency, and dynamics, were found to be variable and sometimes difficult to assess. Numerous information hubs were identified. Providing public access to information on drug shortages to the maximum possible extent is a prerequisite for performing more advanced studies on the problem and identifying solutions. Imposing public service obligations, providing the formal possibility to prescribe unlicensed medicines, and temporary bans on parallel exports are widespread measures. A positive finding of our study was the identification of numerous bottom-up initiatives and organizational frameworks aimed at preventing or mitigating drug shortages. The experiences and lessons drawn from these initiatives should be carefully evaluated, monitored, and presented to a wider international audience for careful appraisal. To be able to find solutions to the problem of drug shortages, there is an urgent need to develop a set of agreed definitions for drug shortages, as well as methodologies for their evaluation and monitoring. This is being progressed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Medicine shortages are a complex global challenge affecting all countries, including South Africa, with shortages of even essential medicines becoming a global problem irrespective of the economic status of countries.
“Over the years, the shortage of medicines has been a challenge to the effective delivery of quality healthcare services worldwide including South Africa [1–10], with shortages of even essential medicines becoming a global problem irrespective of the economic status of countries [11–13].”
From Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications (2020) · cites this paper as [6]
The Introduction reports shortages of WHO-defined essential medicines in several European countries, and the Discussion says shortages occurred in all 28 countries studied regardless of economic development. These passages support the broad concern, but they do not establish shortages in every country or specifically in South Africa. The South Africa wording belongs to a separately cited clause in the printed sentence. (LLM, conf=0.84)
Experimental — accuracy not yet measuredMultiple factors contribute to medicine shortages, including manufacturing and quality problems, production delays, lack of manufacturing capacity, shortage of raw materials, political instability, profitability issues, long lead times, delays in awarding tenders, absence of national contracts on regional code lists, failure of suppliers to meet demand, and failure to pay suppliers.
“Some of the contributing factors to the shortage of medicines include manufacturing and quality problems, production delays, lack of manufacturing capacity, shortage of raw materials, political instability, and profitability issues [5, 6, 8, 9, 18].”
From Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications (2020) · cites this paper as [6]
The Introduction lists manufacturing problems, raw-material shortages, regulatory non-compliance, and limited manufacturing capacity as reasons for shortages; it also identifies economic problems as a group of determinants. It does not specifically identify production delays or political instability as causes, and its discussion of economic problems does not establish profitability issues specifically. The additional factors in the supplied claim are not in the printed citing sentence. (LLM, conf=0.86)
Experimental — accuracy not yet measuredThe origins of medicine shortages are complicated, can differ among regions and countries, and consequently potentially require different strategies to address them.
“The origins of medicine shortages are complicated, can differ among regions and countries, and consequently potentially require different strategies to address them [5, 6, 15].”
From Medicine shortages and challenges with the procurement process among public sector hospitals in South Africa; findings and implications (2020) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Argonaute—a database for gene regulation by mammalian microRNAs
Shahi, P., Loukianiouk, S., Bohne-Lang, A., Kenzelmann, M., Küffer, S., Maertens, S., Eils, R., Gröne, H.-J., Gretz, N., & Brors, B. (2005) · Nucleic Acids Res. · doi:10.1093/nar/gkj093 · Cited by 45,811 · see citing works
Godman, B., Shrank, W. H., Andersen, M. T., Berg, C. L., Bishop, I., Burkhardt, T. H., Garuolienè, K., Herholz, H., Joppi, R., Kalaba, M., et al. (2010) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.10.72 · Cited by 154 · cited 1× · see citing works
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationGodman, B., Wettermark, B., van Woerkom, M., Fraeyman, J., Alvarez-Madrazo, S., Berg, C., Bishop, I., Bucsics, A., Campbell, S., Finlayson, A., et al. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00106 · Cited by 146 · cited 1× · see citing works
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationEffects on Patient Care Caused by Drug Shortages: A Survey
McLaughlin, M. M., Kotis, D., Thomson, K., Harrison, M., Fennessy, G., Postelnick, M., & Scheetz, M. (2013) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2013.19.9.783 · Cited by 143 · cited 2× · see citing works
“Drug shortages have an indisputable impact on public health, especially when they cause a delay in starting treatment or difficulty in its continuation, lowering or omitting doses, increasing costs of treatment, selection of patients, or putting an increased administrative burden on health care staff (Ventola, 2011; M…”
BackgroundInsights into European Drug Shortages: A Survey of Hospital Pharmacists
Pauwels, K., Simoens, S., Casteels, M., & Huys, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119322 · Cited by 121 · cited 5× · see citing works
“The majority of hospital pharmacists, responding to questions in another pan-European survey, indicated increased hospital costs, pharmacy or personnel costs, and the use of more expensive alternatives as frequently or always occurring consequences of drug shortages (Pauwels et al., 2015).”
BackgroundInfluentialSelf-citationFerrario, A., Araja, D., Bochenek, T., Catic, T., Dankó, D., Dimitrova, M., Fürst, J., Greičiūtė-Kuprijanov, I., Hoxha, I., Jakupi, A., et al. (2017) · PharmacoEconomics (Auckland) · doi:10.1007/s40273-017-0559-4 · Cited by 120 · cited 1×
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationNational survey on the effect of oncology drug shortages on cancer care.
McBride, A., Holle, L. M., Westendorf, C., Sidebottom, M., Griffith, N. L., Muller, R., & Hoffman, J. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120563 · Cited by 117 · cited 1×
“…in the USA and Canada, but subsequently in a number of European countries and other continents (Morrison, 2011; Ventola, 2011; Birgli, 2013; McBride et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De Weerdt et al., 2015b, 2017b;…”
BackgroundPauwels, K., Huys, I., Casteels, M., & Simoens, S. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-438 · Cited by 100 · cited 1× · see citing works
“%) and medicines defined as essential by the WHO (52%; Pauwels et al., 2014; World Health Organization, 2017).”
BackgroundSelf-citationVoncina, L., Strizrep, T., Godman, B., Bennie, M., Bishop, I., Campbell, S., Vlahović-Palčevski, V., & Gustafsson, L. (2011) · Expert review of pharmacoeconomics & outcomes research · doi:10.1586/erp.11.42 · Cited by 91 · cited 1× · see citing works
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationMalmström, R. E., Godman, B., Diogène, E., Baumgärtel, C., Bennie, M., Bishop, I., Brzezinska, A., Bucsics, A., Campbell, S., Ferrario, A., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00039 · Cited by 90 · cited 1× · see citing works
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationCacace, M., Ettelt, S., Mays, N., & Nolte, E. (2013) · Health Policy · doi:10.1016/j.healthpol.2013.03.020 · Cited by 85 · cited 1× · see citing works
“…of the global problem of drug shortages, based on a number of cases selected from countries of Europe and Western Asia, characterized by different epidemiologies, geographies, GDPs per capita, levels of spending on health care, and approaches to the pricing of medicines (Cacace et al., 2013).”
BackgroundCauses of drug shortages in the legal pharmaceutical framework.
Weerdt, E. D., Simoens, S., Hombroeckx, L., Casteels, M., & Huys, I. (2015) · Regulatory toxicology and pharmacology : RTP · doi:10.1016/j.yrtph.2015.01.005 · Cited by 82 · cited 5× · see citing works
“…which 26 very different definitions for drug shortages were identified globally in 2015 across a wide array of sources, including: national laws, governmental and professional organizations, and scientific papers (De Weerdt et al., 2015a), as well as other recent studies (De Weerdt et al., 2017b).”
BackgroundInfluentialSelf-citationBogaert, P., Bochenek, T., Prokop, A., & Pilc, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125691 · Cited by 80 · cited 3× · see citing works
“We identified and addressed four major themes: (a) defining drug shortages, (b) their dynamics and perception, (c) their determinants, and (d) the role of the European and national institutions in coping with the problem (Bogaert et al., 2015).”
BackgroundSelf-citationYang, C., Wu, L., Cai, W., Zhu, W., Shen, Q., Li, Z., & Fang, Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165183 · Cited by 70 · cited 1× · see citing works
“…et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De Weerdt et al., 2015b, 2017b; Pauwels et al., 2015; Alsheikh et al., 2016; Awad et al., 2016; Yang et al., 2016; Heiskanen et al., 2017; Mazer-Amirshahi et al., 2017; Walker et al., 2017).”
Drug shortages in developed countries—reasons, therapeutic consequences, and handling
Dill, S., & Ahn, J. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1747-1 · Cited by 66 · cited 2× · see citing works
“…ongoing collaborative relationships among all the stakeholders (including manufacturers and professional organizations) and also internally (within an organization), as well as having keen foresight and acting proactively, as opposed to just reactively, to a given situation (Dill and Ahn, 2014).”
BackgroundMoon, J. C., Godman, B., Petzold, M., Alvarez-Madrazo, S., Bennett, K., Bishop, I., Bucsics, A., Hesse, U., Martin, A., Simoens, S., et al. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00219 · Cited by 64 · cited 1× · see citing works
“Learning from other countries’ experiences should not be underestimated or underutilized in shaping local or national pharmaceutical policies (Godman et al., 2010, 2014; Vončina et al., 2011; Malmström et al., 2013; Moon et al., 2014; Ferrario et al., 2017).”
BackgroundSelf-citationToward a European definition for a drug shortage: a qualitative study
Weerdt, E. D., Simoens, S., Casteels, M., & Huys, I. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00253 · Cited by 58 · cited 5× · see citing works
“…which 26 very different definitions for drug shortages were identified globally in 2015 across a wide array of sources, including: national laws, governmental and professional organizations, and scientific papers (De Weerdt et al., 2015a), as well as other recent studies (De Weerdt et al., 2017b).”
BackgroundInfluentialSelf-citationMedicine shortages in Fiji: A qualitative exploration of stakeholders’ views
Walker, J., Chaar, B. B., Vera, N., Pillai, A. S., Lim, J. S., Bero, L., & Moles, R. J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0178429 · Cited by 57 · cited 1× · see citing works
“…et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De Weerdt et al., 2015b, 2017b; Pauwels et al., 2015; Alsheikh et al., 2016; Awad et al., 2016; Yang et al., 2016; Heiskanen et al., 2017; Mazer-Amirshahi et al., 2017; Walker et al., 2017).”
Heiskanen, K., Ahonen, R., Kanerva, R., Karttunen, P., & Timonen, J. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179479 · Cited by 51 · cited 7× · see citing works
“Just recently, two draft definitions of drug shortages were prepared under the auspices of the WHO (Heiskanen et al., 2017).”
BackgroundInfluentialClinical, Economic and Policy Implications of Drug Shortages in the European Union
De Weerdt, E., Simoens, S., Casteels, M., & Huys, I. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-016-0264-z · Cited by 50 · cited 4× · see citing works
“…which 26 very different definitions for drug shortages were identified globally in 2015 across a wide array of sources, including: national laws, governmental and professional organizations, and scientific papers (De Weerdt et al., 2015a), as well as other recent studies (De Weerdt et al., 2017b).”
BackgroundInfluentialSelf-citationImpact of shortages of injectable oncology drugs on patient care.
Goldsack, J., Reilly, C., Bush, C. G., McElligott, S., Bristol, M. N., Motanya, U. N., Field, R., Vozniak, J., Wong, Y., Schwartz, J. S., et al. (2014) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp130569 · Cited by 49 · cited 4× · see citing works
“…shortage during the previous 12 months, 64% reported that their facility had completely run out of at least one injectable oncology drug during that period of time and 25% reported that one or more safety events had occurred at their facility as a result of drug shortages (Goldsack et al., 2014).”
BackgroundInfluentialU.S. drug shortages for medications used in adult critical care (2001–2016)
Mazer-Amirshahi, M., Goyal, M., Umar, S. A., Fox, E., Zocchi, M., Hawley, K., & Pines, J. (2017) · Journal of critical care · doi:10.1016/j.jcrc.2017.06.005 · Cited by 47 · cited 1× · see citing works
“…et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De Weerdt et al., 2015b, 2017b; Pauwels et al., 2015; Alsheikh et al., 2016; Awad et al., 2016; Yang et al., 2016; Heiskanen et al., 2017; Mazer-Amirshahi et al., 2017; Walker et al., 2017).”
Weerdt, E. D., Rijdt, T. D., Simoens, S., Casteels, M., & Huys, I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174556 · Cited by 40 · cited 4× · see citing works
“…which 26 very different definitions for drug shortages were identified globally in 2015 across a wide array of sources, including: national laws, governmental and professional organizations, and scientific papers (De Weerdt et al., 2015a), as well as other recent studies (De Weerdt et al., 2017b).”
BackgroundInfluentialSelf-citationA Quantitative Analysis of the Causes of Drug Shortages in Jordan: A Supply Chain Perspective
Awad, H., Al-Zu'bi, Z. M. F., & Abdallah, A. (2016) · International Business Research · doi:10.5539/ibr.v9n6p53 · Cited by 39 · cited 2× · see citing works
“Drug shortages has been the focus of academic and practitioner research, initially in the USA and Canada, but subsequently in a number of European countries and other continents (Morrison, 2011; Ventola, 2011; Birgli, 2013; McBride et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butt…”
BackgroundHow the US Food and Drug Administration can solve the prescription drug shortage problem.
Schweitzer, S. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301239 · Cited by 37 · cited 2× · see citing works
“…will likely threaten the various stakeholder groups’ values and require moral trade-offs, difficult Frontiers in Pharmacology | www.frontiersin.org 3 January 2018 | Volume 8 | Article 942 choices within health care systems, and reordering priorities (Lipworth and Kerridge, 2013; Schweitzer, 2013).”
BackgroundAlsheikh, M., Seoane-Vazquez, E., Rittenhouse, B., Fox, E. R., & Fanikos, J. (2016) · Hospital Pharmacy · doi:10.1310/hpj5105-370 · Cited by 29 · cited 1× · see citing works
“…et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De Weerdt et al., 2015b, 2017b; Pauwels et al., 2015; Alsheikh et al., 2016; Awad et al., 2016; Yang et al., 2016; Heiskanen et al., 2017; Mazer-Amirshahi et al., 2017; Walker et al., 2017).”
The new regulatory tools of the 2016 Health Law to fight drug shortages in France.
Bocquet, F., Degrassat-Théas, A., Peigné, J., & Paubel, P. (2017) · Health Policy · doi:10.1016/j.healthpol.2017.03.007 · Cited by 27 · cited 1× · see citing works
“…in starting treatment or difficulty in its continuation, lowering or omitting doses, increasing costs of treatment, selection of patients, or putting an increased administrative burden on health care staff (Ventola, 2011; McLaughlin et al., 2013; Bocquet et al., 2017; De Weerdt et al., 2017b).”
BackgroundPotential Association between Drug Shortages and High‐Cost Medications
Fox, E., & Tyler, L. (2017) · Pharmacotherapy · doi:10.1002/phar.1861 · Cited by 27 · cited 2× · see citing works
“Based on this, the clinician checklist was proposed that includes four steps: (a) assessment of clinical use; (b) check of purchasing and inventory practices; (c) evaluation of operational opportunities; and (d) communication about the issues (Fox and Tyler, 2017).”
BackgroundMethodDrug shortages and implications for pediatric patients.
Butterfield, L., Cash, J., & Pham, K. (2015) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-20.2.149 · Cited by 27 · cited 1× · see citing works
“…continents (Morrison, 2011; Ventola, 2011; Birgli, 2013; McBride et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butterfield et al., 2015; De Weerdt et al., 2015b, 2017b; Pauwels et al., 2015; Alsheikh et al., 2016; Awad et al., 2016; Yang et al., 2016;…”
BackgroundAn audit of drug shortages in a community pharmacy practice
Costelloe, E., Guinane, M., Nugent, F., Halley, O., & Parsons, C. (2015) · Irish Journal of Medical Science · doi:10.1007/s11845-014-1139-7 · Cited by 24 · cited 2× · see citing works
“Drug shortages has been the focus of academic and practitioner research, initially in the USA and Canada, but subsequently in a number of European countries and other continents (Morrison, 2011; Ventola, 2011; Birgli, 2013; McBride et al., 2013; Costelloe et al., 2014; Goldsack et al., 2014; Bogaert et al., 2015; Butt…”
BackgroundWhy drug shortages are an ethical issue.
Lipworth, W., & Kerridge, I. (2013) · Australasian Medical Journal · doi:10.4066/amj.2013.1869 · Cited by 16 · cited 3×
“…will likely threaten the various stakeholder groups’ values and require moral trade-offs, difficult Frontiers in Pharmacology | www.frontiersin.org 3 January 2018 | Volume 8 | Article 942 choices within health care systems, and reordering priorities (Lipworth and Kerridge, 2013; Schweitzer, 2013).”
BackgroundTime Investment in Drug Supply Problems by Flemish Community Pharmacies
Weerdt, E. D., Simoens, S., Casteels, M., & Huys, I. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00568 · Cited by 11 · cited 4×
“…which 26 very different definitions for drug shortages were identified globally in 2015 across a wide array of sources, including: national laws, governmental and professional organizations, and scientific papers (De Weerdt et al., 2015a), as well as other recent studies (De Weerdt et al., 2017b).”
BackgroundInfluentialSelf-citationDrug Shortages and Patient Safety: An Overview of Essential Information for the Infusion Nurse
McLaughlin, M. M., & Skoglund, E. (2015) · Journal of Infusion Nursing · doi:10.1097/nan.0000000000000101 · Cited by 10 · cited 1× · see citing works
“In the USA, the majority of shortages were reported to occur among sterile injectable medications (McLaughlin and Skoglund, 2015).”
BackgroundRuiz, A. M. C., & Greef, G. D. (2020) · Innovative Citizen Participation and New Democratic Institutions · doi:10.1787/9789264060616-3-en · Cited by 7
Drug Shortages and Tipping Points
Wenzel, R. (2015) · Headache · doi:10.1111/head.12689 · Cited by 2 · cited 1×
“(Wenzel, 2015).”
Flagged first, then by citations
21 of the 56 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Desabastecimientos de Medicamentos: Un Problema Sin Resolver (2015). INFAC, Inf Farmacoter la Comarc, Vol. 23. Available online at: https://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_infac/es_cevime/adjuntos/INFAC_Vol_23_N_7_Desabastecimientos.pdf
- Kavanagh J. (2017). How Pharmaceutical Supply Chains Can Be Managed to Minimise the Number of Medicines Shortages, Unpublished Master's thesis, University College Dublin, Ireland.
- Pfeffer K. Mozolová B. (2018). Re-export of drugs in the Slovak Republic vol. 2 – the Act [Internet]. Available: https://www.twobirds.com/en/news/articles/2017/uk/ils/re-export-of-drugs-in-the-slovak-republic-vol-2-the-act
- Ventola C. L. (2011). The drug shortage crisis in the United States: causes, impact, and management strategies. P T. 36, 740– 757. 22346307 PMC3278171
Cited by
Sorted by citations
Drug Shortage: Causes, Impact, and Mitigation Strategies
Shukar, S., Zahoor, F., Hayat, K., Saeed, A., Gillani, A. H., Omer, S., Hu, S., Babar, Z., Fang, Y., & Yang, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.693426 · Cited by 348 · see citing works
Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries
Godman, B., Egwuenu, A. J., Haque, M., Malande, O. O., Schellack, N., Kumar, S., Saleem, Z., Sneddon, J., Hoxha, I., Islam, S., et al. (2021) · Life · doi:10.3390/life11060528 · Cited by 238 · see citing works
Self-citationOgunleye, O. O., Basu, D., Mueller, D., Sneddon, J., Seaton, R. A., Yinka-Ogunleye, A. F., Wamboga, J., Miljković, N., Mwita, J. C., Rwegerera, G. M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01205 · Cited by 208 · see citing works
Self-citationGodman, B., Haque, M., McKimm, J., Abu Bakar, M., Sneddon, J., Wale, J., Campbell, S., Martin, A. P., Hoxha, I., Abilova, V., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1700947 · Cited by 171 · see citing works
Self-citationMedicine Shortages: Gaps Between Countries and Global Perspectives
Acosta, A., Vanegas, E. P., Rovira, J., Godman, B., & Bochenek, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00763 · Cited by 147 · see citing works
Self-citationGodman, B., Basu, D., Pillay, Y. G., Mwita, J. C., Rwegerera, G. M., Paramadhas, B. D. A., Tiroyakgosi, C., Okwen, P., Niba, L. L., Nonvignon, J., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00108 · Cited by 141 · see citing works
“…areas and situations to provide future guidance (Godman et al., 2010; Godman et al., 2014a; Godman et al., 2014b; Campbell et al., 2015; Godman et al., 2015; Ermisch et al., 2016; Bochenek et al., 2017; Moorkens et al., 2017; Godman et al., 2018; Vella Bonanno et al., 2019; Godman et al., 2020).”
BackgroundMethodSelf-citationModisakeng, C., Matlala, M., Godman, B., & Meyer, J. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05080-1 · Cited by 130 · see citing works
“There are also considerable shortages in other continents and countries including other low and middle income countries (LMICs) across South America and wider [5, 6, 8, 9].”
BackgroundInfluentialSelf-citationGodman, B., McCabe, H., Leong, T., Mueller, D., Martin, A., Hoxha, I., Mwita, J., Rwegerera, G., Massele, A., Costa, J. D. O., et al. (2020) · Expert review of pharmacoeconomics & outcomes research · doi:10.1080/14737167.2020.1734456 · Cited by 87 · see citing works
Self-citationNew regulatory strategies to manage medicines shortages in Europe
Musazzi, U. M., Giorgio, D. D., & Minghetti, P. (2020) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2020.119171 · Cited by 71 · see citing works
“Such fragmentation has also been evident in the communication strategies adopted by the different EU Member States (Bochenek et al., 2018).”
BackgroundInfluentialHaque, M., Islam, S., Iqbal, S., Urmi, U., Kamal, Z., Rahman, A., Kamal, M., Haque, M., Jahan, I., Islam, Z., et al. (2020) · Bangladesh Journal of Medical Science · doi:10.3329/bjms.v19i0.48106 · Cited by 58 · see citing works
Self-citationGodman, B., Fadare, J. O., Kwon, H.-Y., Dias, C. Z., Kurdi, A. B., Godói, I. P. D., Kibuule, D., Hoxha, I., Opanga, S. A., Saleem, Z., et al. (2021) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0273 · Cited by 59 · see citing works
“However, there are concerns with potential shortages if prices of generics are too low, exacerbating current concerns with shortages of medicines across countries [48,213,214].”
BackgroundSelf-citationHow to address medicines shortages: Findings from a cross-sectional study of 24 countries
Vogler, S., & Fischer, S. (2020) · Health Policy · doi:10.1016/j.healthpol.2020.09.001 · Cited by 62 · see citing works
Godman, B., Grobler, C., Van-De-Lisle, M., Wale, J., Barbosa, W. B., Massele, A. Y., Opondo, P. R., Petrova, G. I., Tachkov, K., Sefah, I. A., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1684473 · Cited by 48 · see citing works
Self-citationShen, J., Bu, F., Ye, Z., Zhang, M., Ma, Q., Yan, J., & Huang, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1373642 · Cited by 58 · see citing works
Miljković, N., Godman, B., van Overbeeke, E., Kovačević, M., Tsiakitzis, K., Apatsidou, A., Nikopoulou, A., Yubero, C. G., Horcajada, L. P., Stemer, G., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00157 · Cited by 38
“Managing shortages is often seen as solely the task of a hospital pharmacist, confirmed by studies conducted in Belgium and the EAHP where hospital pharmacists are reported to spend a significant time mitigating shortages (2, 44).”
BackgroundSelf-citationVogler, S. (2024) · Health Policy · doi:10.1016/j.healthpol.2024.105030 · Cited by 38 · see citing works
Pricing of oral generic cancer medicines in 25 European countries; findings and implications
Godman, B., Hill, A., Simoens, S., Kurdi, A., Gulbinovič, J., Martin, A., Timoney, A., Gotham, D., Wale, J., Bochenek, T., et al. (2019) · GaBI Journal · doi:10.5639/gabij.2019.0802.007 · Cited by 37
Self-citationSaid, A., Goebel, R., Ganso, M., Zagermann-Muncke, P., & Schulz, M. (2018) · Health Policy · doi:10.1016/j.healthpol.2018.09.005 · Cited by 37 · see citing works
Results of EAHP’s 2019 Medicines Shortages Survey
Miljković, N., Batista, A., Polidori, P., Kohl, S., & Horák, P. (2020) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2020-002341 · Cited by 41 · see citing works
“4 However, the survey showed that only a small percentage of professionals (8% of OHCPs/5% of HPs/1% of PHYs) are aware that such groups are organised regionally.”
InfluentialSelf-citationProspective Risk Assessment of Medicine Shortages in Europe and Israel: Findings and Implications
Miljković, N., Godman, B., Kovačević, M., Polidori, P., Tzimis, L., Hoppe‐Tichy, T., Saar, M., Antofie, I., Horváth, L., Rijdt, T. D., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00357 · Cited by 38 · see citing works
“In addition, the healthcare professionals freely participated and no patients were involved, as in line with similar such studies in this and related fields (Godman et al., 2014; Moon et al., 2014; Bochenek et al., 2017).”
BackgroundInfluentialSelf-citationRavela, R., Lyles, A., & Airaksinen, M. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08309-3 · Cited by 30
“Methods In most European countries and in the United States, market authorisation holders are obligated to notify national authorities of impending drug shortages [20, 24].”
BackgroundBeetsma, R., Burgoon, B., Nicoli, F., de Ruijter, A., & Vandenbroucke, F. (2021) · European Journal of Public Health · doi:10.1093/eurpub/ckaa201 · Cited by 24 · see citing works
Batista, A., Miljković, N., Polidori, P., & Kohl, S. (2019) · European Journal of Hospital Pharmacy: Science and Practice · doi:10.1136/ejhpharm-2019-001911 · Cited by 22
Self-citationBilal, A. I., Bititci, U., & Fenta, T. G. (2024) · Pharmacy · doi:10.3390/pharmacy12050132 · Cited by 24 · see citing works
“Studies from various contexts have identified specific strategies such as establishing information systems, imposing public service obligations, influencing trade rules, and forming committees to collaboratively tackle shortages [97].”
BackgroundVideau, M., Chemali, L., Stucki, C., Saavedra-Mitjans, M., Largana, S., Guérin, A., Bonnabry, P., Delhauteur, B., Hees, T. V., Lebel, D., et al. (2019) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v72i1.2863 · Cited by 20 · see citing works
“9) Radioisotopes 0 (0) 0 (0) 0 (0) 1 (4) 0 (0) 1 (0.”
InfluentialFalco, M. F., Meyer, J. C., Putter, S. J., Underwood, R., Nabayiga, H., Opanga, S. A., Miljković, N., Nyathi, E., & Godman, B. (2023) · Healthcare · doi:10.3390/healthcare11131838 · Cited by 17 · see citing works
Self-citationDrug shortages in China: a cross-sectional study
Song, Y.-Y., Li, J., Zhao, F., & Jin, P.-F. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09295-w · Cited by 18 · see citing works
sorato, M. M., Davari, M., Asl, A. A., Soleymani, F., & Kebriaeezadeh, A. (2020) · Journal of Pharmaceutical Health Services Research · doi:10.1111/jphs.12379 · Cited by 18 · see citing works
Bade, C., Olsacher, A., Boehme, P., Truebel, H., & Fehring, L. (2023) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2023.05.007 · Cited by 15 · see citing works
Beck, M. P., Buckley, J., & O’Reilly, S. J. (2019) · International Review of Administrative Sciences · doi:10.1177/0020852318815330 · Cited by 24 · see citing works
“A number of researchers have, like us, investigated initiatives and approaches to the problem of DSs (Bochenek et al., 2018; De Weerdt et al., 2017), and it is likely that the ongoing complexity of the issue will engage researchers for some time.”
BackgroundAlAzmi, A., & AlRashidi, F. (2019) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s198375 · Cited by 17 · see citing works
Causes and management of drug shortages: A scoping review
Cornelissen, N., Zielhuis, S. W. J., van den Bemt, P. M. L. A., & van den Bemt, B. J. F. (2025) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2025.10.008 · Cited by 16 · see citing works
Godman, B., Władysiuk, M., McTaggart, S., Kurdi, A., Allocati, E., Jakovljevic, M., Kalemeera, F., Hoxha, I., Nachtnebel, A., Sauermann, R., et al. (2021) · BioMed Research International · doi:10.1155/2021/9996193 · Cited by 15 · see citing works
Self-citationEffects of geopolitical strain on global pharmaceutical supply chain design and drug shortages
Pava, M. L. S.-D. L., & Tucker, E. L. (2023) · European Journal of Operational Research · doi:10.1016/j.ejor.2025.05.002 · Cited by 14
“Drug shortages affect the quality and continuity of patients’ treatments, which endangers the patient’s health and increases the costs of healthcare (Bochenek et al., 2018).”
Drug shortages as a result of parallel export in Poland – Pharmacists’ opinions
Zaprutko, T., Kopciuch, D., Bronisz, M., Michalak, M., Kus, K., & Nowakowska, E. (2020) · Health Policy · doi:10.1016/j.healthpol.2020.03.003 · Cited by 18 · see citing works
Postma, D. J., de Smet, P. D., Wied, C. G. G.-D., Leufkens, H., & Mantel-Teeuwisse, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01243 · Cited by 14 · see citing works
“Similar initiatives have been launched inside (Bochenek et al., 2017) and outside the EU.”
BackgroundMiljković, N., van Overbeeke, E., Godman, B., Kovačević, M., Anastasi, A., Bochenek, T., Huys, I., & Miljković, B. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00407 · Cited by 14 · see citing works
“The authors have previously assessed systematic frameworks and legislative processes for mitigating against drug shortages (40), the extent of medicine shortages in Europe, especially in hospitals, (4) and the extent of using risk-assessment procedures in hospitals to help mitigate the impact of shortages (34).”
BackgroundSelf-citationIndicator of access to medicines in relation to the multiple dimensions of access.
Garcia, M., Barbosa, M. M., Silva, R., Reis, E., Alvares, J., Acúrcio, F. D. A., Godman, B., & Guerra, A. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0031 · Cited by 13
Self-citationProposal for Handling of Medicine Shortages Based on a Comparison of Retrospective Risk Analysis
Turbucz, B., Major, M., Zelkó, R., & Hankó, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19074102 · Cited by 14 · see citing works
“Spain Spanish Agency of Medicines and Medical Products (AEMPS) The number of available units is below the level of national or local consumption needs [25].”
BackgroundSelf-citationVogler, S., Habimana, K., & Haasis, M. A. (2022) · The International Journal of Health Planning and Management · doi:10.1002/hpm.3444 · Cited by 15 · see citing works
Barriers and facilitators of exploiting the potential of value-added medicines
Petykó, Z. I., Inotai, A., Holtorf, A., Brixner, D. I., & Kaló, Z. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1758558 · Cited by 15 · see citing works
“Medicine shortages are global health care system phenomena occurring in all countries regardless of income level and the number of active drug shortages have been increasing recently [24,25].”
BackgroundSelf-citationSallam, M., Oliver, A., Allam, D., Kassem, R., & Damani, M. (2024) · Cureus · doi:10.7759/cureus.76377 · Cited by 9 · see citing works
Ethical issues in implementing artificial intelligence in healthcare
Koshechkin, K., & Khokholov, A. (2024) · Медицинская этика · doi:10.24075/medet.2024.006 · Cited by 10 · see citing works
Mbonane, H., Sibanda, M., Godman, B., Meyer, J. C., & Matlala, M. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100233 · Cited by 11 · see citing works
Self-citationPatients perspectives on drug shortages in six European hospital settings – a cross sectional study
Poje, D. K., Kifer, D., Huys, I., Miranda, J., Jenzer, H., Miljković, N., Hoppe-Tichy, T., Bochniarz, M., Frontini, R., Schwartz, D. G., et al. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-06721-9 · Cited by 10
Self-citationDrug shortages in hospitals: Actors' perspectives.
Poulsen, J. H., Dieckmann, P., Clemmensen, M., & Nørgaard, L. (2021) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2021.05.001 · Cited by 9 · see citing works
Santhireswaran, A., Chu, C., Kim, K. C., Gaudette, É., Burry, L. D., Clement, F. M., Suda, K. J., & Tadrous, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293497 · Cited by 10 · see citing works
Ravela, R., Airaksinen, M., & Lyles, A. (2023) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-023-00646-w · Cited by 8
Ríos-Blancas, M., Lamadrid-Figueroa, H., Betancourt-Cravioto, M., & Lozano, R. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250172 · Cited by 8 · see citing works
“On the other hand, specific courses or workshops about indications or contraindications for vaccination [44, 45], and avoiding wasting vaccines and supplies [39, 40, 47] are required, as well as the development of summary clinic guidelines or electronic applications for accompaniment in daily practice [15].”
BackgroundMedicine Shortages in Serbia: Pharmacists’ Standpoint and Potential Solutions for a Non-EU Country
Lješković, N. J., Galović, A. J., Stojkov, S., Jojić, N., & Gigov, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040448 · Cited by 10 · see citing works
“In line with this, another barrier in successful navigation of a drug shortage is the lack of an integrated IT system in Serbia, supplied with information on ongoing and future shortages [46].”
BackgroundPoulsen, J. H., Rishøj, R. M., Fischer, H., Kart, T., Nørgaard, L., Sevel, C., Dieckmann, P., & Clemmensen, M. (2019) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098619859995 · Cited by 8
“…is the first study to combine incident reporting with focus group inter-views to explore the challenges and underlying problems related to DCs. 8, 31, 32 Understanding the challenges and risk of errors associated with DC related to drug shortage is crucial in the process of improving patient…”
BackgroundGodman, B., Tubić, B., Allocati, E., Władysiuk, M., McTaggart, S., Kurdi, A., Haque, M., MacBride-Stewart, S., Kalemeera, F., Massele, A., et al. (2022) · Journal of Applied Pharmaceutical Sciences · doi:10.7324/japs.2022.120306 · Cited by 7 · see citing works
Self-citationMedicines Shortages Reporting Systems (MSRS): An exploratory review of access and sustainability
Yaroson, E. V., Quinn, G., & Breen, L. (2024) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2024.02.010 · Cited by 6 · see citing works
human factors: the pharmaceutical supply chain as a complex sociotechnical system
Edwards, B. D., Gloor, C. A., Toussaint, F., Guan, C.-F., & Furniss, D. (2020) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzaa102 · Cited by 6
Garcia, M. M., Azevedo, P. S., Mirelman, A. J., Safatle, L. P., Iunes, R. F., Bennie, M., Godman, B., & Guerra, A. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00370 · Cited by 7 · see citing works
“Medicine losses and shortages occur simultaneously with concerns with the quality of pharmaceuticals in several developing countries (Hassali et al., 2014; Fadare et al., 2016; Bochenek et al., 2017; Acosta et al., 2019), representing critical inefficiencies of public services resulting in increased patient expenditur…”
BackgroundSelf-citationSánchez, D. I. R., & Vogler, S. (2023) · Pharmacy · doi:10.3390/pharmacy11040120 · Cited by 5 · see citing works
“the national definitions slightly vary across countries [7,21,22].”
BackgroundBeck, M. P., & Buckley, J. (2022) · The Journal of Medicine Access · doi:10.1177/27550834221123425 · Cited by 5
Jenzer, H., Sadeghi, L., Maag, P., Scheidegger-Balmer, F., Uhlmann, K., & Groesser, S. (2019) · Pharmaceutical Supply Chains - Medicines Shortages · doi:10.1007/978-3-030-15398-4_1 · Cited by 5
Self-citationTruong, P., Rothe, C. C., & Bochenek, T. (2019) · Pharmaceutical Supply Chains - Medicines Shortages · doi:10.1007/978-3-030-15398-4_3 · Cited by 5
Self-citationGiorgio, D. D., Scrofina, G., Scognamiglio, B., Carluccio, N. D., Tulimiero, R., Pietrosanto, A., Petrone, P., Iure, M. D., Chimenti, M., Pozzetti, E., et al. (2019) · Medicine Access @ Point of Care · doi:10.1177/2399202619856859 · Cited by 5
Antibiotic shortages in Europe: Another question of prices?
Garattini, L., Finazzi, B., & Mazzone, A. (2024) · European journal of internal medicine · doi:10.1016/j.ejim.2024.03.018 · Cited by 4
Nyika, A., Ngara, B., Mutingwende, I., & Gwaza, L. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07995-3 · Cited by 3 · see citing works
Moral reasoning perspectives of community pharmacists in situations of drug shortages
Kruijtbosch, M., Floor‐Schreudering, A., van Leeuwen, E., Göttgens, W., & Bouvy, M. L. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.11.012 · Cited by 6 · see citing works
Schleipman, A. R., & Todorova, I. (2020) · Narrative Inquiry in Bioethics · doi:10.1353/nib.2020.0012 · Cited by 4
“…are many common contributing factors (manufacturing plant problems, market consolidation, delayed shortage announcements), differing policy responses have been proposed in individual nations and coordinated member states (Bocquet, Degrassat-Théas, Peigné, & Paubel, 2017; Bochenek et al., 2018).”
Yi, Q., Yang, N., Zeng, L., Huang, L., Zou, K., Chen, J.-J., Luo, J., Zhang, M., Diao, S., Yu, Q., et al. (2026) · BMC Public Health · doi:10.1186/s12889-026-26834-2 · Cited by 3 · see citing works
“Furthermore, Canada, the European Union, and China have prioritized transparency in shortage reporting by promptly disclosing information on current and resolved shortages through public databases [13, 48].”
Policy Effectiveness in Managing Drug Shortages: Evidence From South Korea (2015–2024)
Yu, S. (2025) · World Medical & Health Policy · doi:10.1002/wmh3.70024 · Cited by 3
Wiegel, N., & Mettini, E. (2024) · Медицинская этика · doi:10.24075/medet.2024.015 · Cited by 3 · see citing works
The impact of medicines shortages on pharmaceutical practice
Focșa, A.-V., Bîrsan, M., Drăgan, M., Stan, R. T., Mircea, C., & Stan, C. D. (2022) · Romanian Journal of Pharmaceutical Practice · doi:10.37897/rjphp.2022.1.4 · Cited by 3 · see citing works
State Management of the Sphere of Circulation of Medicines in the Context of the COVID-19 Pandemic
Bukatov, Y., Gimranova, G., & Shanin, S. A. (2021) · The economy strategy and practice · doi:10.51176/1997-9967-2021-3-227-242 · Cited by 3 · see citing works
“The end of the international reference pricing system? Appl Health Econ Health Policy, 14(1), 1-8.”
BackgroundInfluentialPanfilova, G., Самборський, О. С., Терещенко, Л. В., Білик, І. П., & Ціхонь, Г. М. (2025) · Farmatsevtychnyi zhurnal · doi:10.32352/0367-3057.6.25.01 · Cited by 2
Key stakeholders’ views on the causes of medicine stock-outs in Mauritania: A qualitative study
Ahmed, M. A. A., Coulibaly, I. M., Ravinetto, R., Buitrago, V. T., & Dujardin, C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0304930 · Cited by 4 · see citing works
Lan, Y., Meng, C., Sun, L.-H., & Huang, Z. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305383 · Cited by 2 · see citing works
A Literature Review: Drug Supply Chain and Neural Networks
Emmanuel, G., Meyliana, Hidayanto, A., & Prabowo, H. (2022) · 2022 6th International Conference on Information Technology, Information Systems and Electrical Engineering (ICITISEE) · doi:10.1109/icitisee57756.2022.10057939 · Cited by 2
“Bochenek [5] investigated drug shortages in European and West Asian countries.”
BackgroundPoulsen, J. H., Clemmensen, M. H., Nørgaard, L. S., & Dieckmann, P. (2021) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2021.100055 · Cited by 3 · see citing works
“described in the literature, such as delayed, omitted, and/or suboptimal treatment.(1,4,5,9) DSs often present themselves as emergency situations posing a variety of challenges such as the duration of the shortage, the availability of alternatives and the frequency of shortages.”
BackgroundOverview of the causes and management of drug shortages in the United States and in Hungary
Turbucz, B., & Hankó, B. (2020) · Acta Pharmaceutica Hungarica · doi:10.33892/aph.2020.90.170-184 · Cited by 4 · see citing works
Self-citationCreating Coherent Strategies to Combat the Crises of Opioid Scarcity and Abuse.
Hantel, A., Levine, S., & Siegler, M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.1079 · Cited by 2
Tackling Drug Shortages: An In-Depth Systematic Review Protocol
Alshammari, M. K., Alraya, R. A., Aljabri, A. K., Alsaadi, B., Althubyani, M. M., Alamri, S., Alqarni, A., Alenazi, Y. M., Almutairi, A., Alshehri, A., et al. (2025) · Pharmacy Practice · doi:10.18549/pharmpract.2025.2.3176
Ravela, R., Aaltonen, T., Airaksinen, M., & Lyles, A. (2025) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2025.100637 · Cited by 1
Caviglioli, G., Drava, G., Pivetta, L., Meco, C. D., Livoti, E., Paoli, G., Baldassari, S., Ailuno, G., Franchina, M. P., Bonsignore, A., et al. (2025) · Healthcare · doi:10.3390/healthcare13101139 · Cited by 1
“In the literature, a number of publications have dealt with drug shortages by analyzing causes, trends, and impacts in different national systems [17–23], but, to the best of our knowledge, no algorithms similar to ours have ever been disclosed, nor have similar rational tools been developed and…”
Poulsen, J. H., Jensen, S. R., Clemmensen, M. H., Holck, M. V., Uldal, N., Kart, T., Nielsen, G. N., Armandi, H. B., & Hansen, O. L. M. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100322 · Cited by 1 · see citing works
Drug Shortages and Its Effects on Service Delivery among Key Informants (KIs) in Fiji
Raikabakaba, A., Mohammadnezhad, M., Tamani, L., & Gaundan, D. (2022) · Global Journal of Health Science · doi:10.5539/gjhs.v14n5p1 · Cited by 2 · see citing works
“It is estimated that two billion people do not have access to medicines and four million lives per year could be saved in Africa and Southeast Asia with the appropriate treatment and medicine (Bochenek et al., 2018; Marks, 2009; Yadav et al., 2011).”
BackgroundYailian, A.-L., Deville, L., Cahoreau, V., Grosjean, V., Mahlaoui, N., Pergent, M., & Chamouard, V. (2020) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2020.11.001 · Cited by 1
Arsalan, T., Koshechkin, K., & Lebedev, G. (2020) · KES International Conference on Intelligent Decision Technologies · doi:10.1007/978-981-15-5925-9_33 · Cited by 1
The Beginning of Pharmacovigilance in Bosnia and Herzegovina
Martin, K., Tubic, Biljana, Muhovic, & Dinka (2020) · doi:10.35248/2329-6887.20.8.286 · Cited by 1
“In 2018 for the first time since the foundation of the Agency the Annual report on adverse events caused by medical products and medical devices for 2017 was published [24].”
BackgroundGurila, R., Popovici, R., Antal, D., Bob, F., Păcurar, A. T., Predescu, I., Smultea, I., Liga, S., Șușan, M., Anton, A., et al. (2026) · Farmacia · doi:10.31925/farmacia.2026.4.24
Crul, M., Polidori, C., Paolucci, D., Rieutord, A., Silva, P., Hatlelid, L., Riffle, A., Eggers, G., Amerine, L., & Kraemer, I. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261470008
Chirac, O. T., Tăerel, A.-E., Dinu, M., & Ancuceanu, R. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-14893-5
“…instability and low profitability, even when they are therapeutically relevant, particularly in small and highly regulated markets where commercial margins are limited by legislation and subject to over-taxation, as well as vulnerable to fluctuations in demand or supply chain disruptions [63, 64].”
Sugiura, G., Gregory, S., Greco, F., Grant, D., & Patel, N. (2026) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-026-02164-6
“In a survey of drug shortage management across 28 countries in Europe and West Asia, Bochenek et al. outlined the need for agreed definitions and standardised methodologies to reduce duplication of effort [29].”
Knoll, V., Steigenberger, C., Fischer, S., & Vogler, S. (2026) · Health Policy · doi:10.1016/j.healthpol.2026.105566
Wisnu, M., & Khairani, A. (2025) · Journal of Islamic Pharmacy · doi:10.18860/jip.v10i1.32374
“Increased demand can cause drug shortages so that patients receive treatment late and make patients non-compliant [4].”
Szabatura, A. (2023) · Chemistry & Industry · doi:10.1002/cind.10198
Hashmi, B., & Kisa, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137885
“They can impair the quality and effectiveness of patient care, and increase the cost of therapy [54].”
BackgroundShortages of medicines in a psychiatric hospital in Cyprus
Petrou, P., & Sophie, I. (2022) · European Pharmaceutical Journal · doi:10.2478/afpuc-2021-0014
Bojković, J., Radanović, D., Micić, D., Obradović, A., & Popović, D. J. (2026) · Srpski medicinski casopis Lekarske komore · doi:10.5937/smclk7-66267
“[31] otpornost lanaca snabdevanja lekovima i medicinskim sredstvima kao stub zdravstvene bezbednosti : integrativni pregled i okvir upravljanja zasnovan na iskustvima iz prakse pharmaceutical and medical device supply chain resilience as a pillar of healthcare security : an integrative review and…”
Influential김하나 (2026) · Health Policy and Technology · doi:10.1016/j.hlpt.2026.101304
Towards a Basis for Policy Framework for Stockouts and Shortages of Drugs
Calucin, A. C. (2023) · International Conference on Industrial Engineering and Operations Management (IEOM) · doi:10.46254/an12.20220352
“To address this issue, various agencies, groups, and governments have established policies, initiatives, research studies, and guidelines (Ferrario et al., 2017; Bochenek et al., 2018).”
BackgroundIntroduction: Why Is Improving Use of Medicines and Medical Tests Important?
Weekes, L. (2020) · Springer eBooks · doi:10.1007/978-981-15-2333-5_1
- Authors
- Bochenek, T., Abilova, V., Alkan, A., Asanin, B., de Miguel Beriain, I., Besovic, Z., Vella Bonanno, P., Bucsics, A., Davidescu, M., De Weerdt, E., Duborija-Kovacevic, N., Fürst, J., Gaga, M., Gailīte, E., Gulbinovič, J., Gürpınar, E. U., Hankó, B., Hargaden, V., Hotvedt, T. A., Hoxha, I., Huys, I., Inotai, A., Jakupi, A., Jenzer, H., Joppi, R., Laius, O., Lenormand, M.-C., Makridaki, D., Malaj, A., Margus, K., Marković-Peković, V., Miljković, N., de Miranda, J. L., Primožič, S., Rajinac, D., Schwartz, D. G., Šebesta, R., Simoens, S., Slaby, J., Sović-Brkičić, L., Tesar, T., Tzimis, L., Warmińska, E., & Godman, B.
- Affiliations
- Jagiellonian University (PL)
- Ministry of Healthcare (AZ)
- Clalit Health Services (IL)
- Health Insurance Institute of Slovenia (SI)
- Vilnius University (LT)
- Semmelweis University (HU)
- University College Dublin (IE)
- University of Medicine Tirana (AL)
- KU Leuven (BE)
- University for Business and Technology (XK)
- Bern University of Applied Sciences (CH)
- l'Assurance Maladie (FR)
- Institute of Orthopedics Banjica (RS)
- Univerzitetski Klinički Centar Srbije (RS)
- Bar-Ilan University (IL)
- State Institute for Drug Control (CZ)
- Chania General Hospital ”St. George” (GR)
- University of Warsaw (PL)
- Karolinska University Hospital (SE)
- Corresponding author
- Bochenek, Tomasz
- ORCID
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-01-18
- Volume
- 8
- Pages
- 942-942
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC5779072
- OpenAlex
- W2788385076
- Cited by
- 112
- References
- 56
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 12 · 2023: 10 · 2022: 16 · 2021: 16 · 2020: 26 · 2019: 14 · 2018: 3
- FWCI
- 22.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Strathprints: The University of Strathclyde institutional repository (University of Strathclyde) (acceptedVersion, cc-by)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- ARBOR - Bern University of Applied Sciences Repository (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ELTE Digital Institutional Repository (EDIT) (Eötvös Loránd University) (submittedVersion, other-oa)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- BFH: ARBOR
- Funders
- Uniwersytet Jagielloński Collegium Medicum (K/ZDS/006990)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Health Professions › Health Information Management › Healthcare Regulation
- Keywords
- drug shortages, pharmaceutical policy, health care legislation, drug regulation, unlicensed medicines, public service obligations, health care system
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
